AstraZeneca said its antibody cocktail against Covid-19 would - unlike its vaccine - be priced commercially as it negotiates supply contracts with governments around the globe.
"We are looking at a commercial pricing strategy. That is part of our negotiations with governments," Iskra Reic, Astra's executive vice president for vaccines and immune therapies, said in a media call on Thursday.
She added that the group's main objective was to make the shot affordable and broadly available.